Bridgeway Capital Management, LLC Aptinyx Inc. Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.35 - $0.72 $11,760 - $24,192	-33,600 Reduced 21.31%	124,041 $46,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $2.58 $18,870 - $128,120	-49,659 Reduced 23.96%	157,641 $88,000
Q1 2022 May 16, 2022	SELL	$2.27 - $3.62 $113,500 - $181,000	-50,000 Reduced 19.43%	207,300 $471,000
Q4 2021 Feb 14, 2022	SELL	$2.11 - $3.0 $361,654 - $514,200	-171,400 Reduced 39.98%	257,300 $687,000
Q3 2021 Nov 15, 2021	BUY	$2.21 - $2.89 $361,114 - $472,226	163,400 Added 61.59%	428,700 $1 Million
Q1 2021 May 17, 2021	BUY	$2.86 - $4.33 $343,200 - $519,600	120,000 Added 82.59%	265,300 $796,000
Q4 2020 Feb 16, 2021	BUY	$2.93 - $4.3 $161,150 - $236,500	55,000 Added 60.91%	145,300 $503,000
Q3 2020 Nov 16, 2020	SELL	$3.05 - $4.99 $170,800 - $279,440	-56,000 Reduced 38.28%	90,300 $305,000
Q4 2019 Feb 14, 2020	BUY	$2.84 - $4.25 $168,412 - $252,025	59,300 Added 68.16%	146,300 $500,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.08 $261,000 - $354,960	87,000 New	87,000 $304,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.